Publicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (19)

2018

  1. The prognostic impact of additional intrathoracic findings in patients with cancer-related pulmonary embolism

    Clinical and Translational Oncology, Vol. 20, Núm. 2, pp. 230-242

  2. Top ten errors of statistical analysis in observational studies for cancer research

    Clinical and Translational Oncology, Vol. 20, Núm. 8, pp. 954-965

2017

  1. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  2. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1

  3. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  4. FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence

    Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009

  5. Performance of the clinical index of stable febrile neutropenia (CISNE) in different types of infections and tumors

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 386-395

  6. Predicting serious complications in patients with cancer and pulmonary embolism using decision tree modelling: The EPIPHANY Index

    British Journal of Cancer, Vol. 116, Núm. 8, pp. 994-1001

  7. Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer

    Gastric Cancer, Vol. 20, Núm. 3, pp. 465-474

  8. Prognostic value of computed tomography pulmonary angiography indices in patients with cancer-related pulmonary embolism: Data from a multicenter cohort study

    European Journal of Radiology, Vol. 87, pp. 66-75

  9. Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

    European Journal of Cancer, Vol. 84, pp. 212-218

2014

  1. Role of genetic polymorphisms in NFKB-mediated inflammatory pathways in response to primary chemoradiation therapy for rectal cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 90, Núm. 3, pp. 595-602